Beta-peptido sugar-copolymer antimicrobial selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antimicrobial peptides and their synthetic analogues face challenges such as sensitivity to physiological environments, toxicity to host cells, and high costs, as well as limited effectiveness against resistant bacterial strains like MRSA, due to their multiple targets and resistance evolution.
Innovation Solution
Development of β-peptido sugar-copolymers through anionic ring-opening polymerization (ROP) of β-lactams, which form block-like copolymers combining sugar-derived and β-(L)-homoamino acid-derived blocks, creating a double helical structure that selectively targets bacteria while maintaining biocompatibility with mammalian cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural antimicrobial peptides and their synthetic analogues are used, then antimicrobial activity is achieved, but sensitivity to physiological environment and toxicity to host cells occur
Solution Approach 1:
The patent employs composite materials by combining β-peptide blocks with sugar-derived blocks to create copolymers that exhibit both antimicrobial activity and reduced host cell toxicity. The β-peptide component provides antimicrobial function while the sugar component enhances biocompatibility and reduces hemolysis, resolving the contradiction between efficacy and safety
Solution Approach 2:
The invention applies local quality by creating block copolymers where different segments have distinct functions: the β-peptide blocks provide antimicrobial activity while the sugar blocks provide biocompatibility. This spatial separation of functions allows the material to exhibit both high antimicrobial efficacy and low host cell toxicity simultaneously
2Adaptability or versatility
If conventional antimicrobial peptides are used, then broad spectrum activity is achieved, but resistance evolution occurs
Solution Approach 1:
The patent utilizes parameter changes by modifying the chemical structure from conventional α-peptides to β-peptides, which form different secondary structures (alpha-helices or beta-sheets) that create novel antimicrobial mechanisms. This structural parameter change results in new modes of action that bacteria have not developed resistance against, while maintaining broad spectrum activity
3Stability of the object's composition
If synthetic peptide analogues are developed, then stability is improved, but manufacturing cost increases
Solution Approach 1:
The invention applies parameter changes by using β-peptide chemistry which inherently provides enhanced enzymatic stability compared to α-peptides. The β-peptide backbone structure resists proteolytic degradation, achieving high stability while the block copolymer architecture enables scalable synthesis through controlled polymerization, balancing stability with manufacturability
4Reliability
If multiple target mechanisms are employed, then antimicrobial efficacy is enhanced, but selectivity between bacteria and host cells decreases
Solution Approach 1:
The patent implements local quality by creating block copolymers where the β-peptide blocks specifically target bacterial membranes through their amphiphilic conformations, while the sugar blocks provide biocompatibility and reduce non-specific interactions with host cells. This spatial differentiation enhances both efficacy and selectivity
Solution Approach 2:
The composite nature of the β-peptide-sugar copolymers allows combination of targeting functionality with selective recognition. The β-peptide component provides antimicrobial action while the sugar component enhances selectivity for bacterial over host cell targets, resolving the contradiction between efficacy and selectivity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The β-peptido sugar-copolymers demonstrate effective antibacterial activity against Gram-positive bacteria, including MRSA, with no hemolysis and improved biocompatibility, showing promise for treating skin and soft tissue infections with enhanced selectivity and stability.
Implementation Method 1
Development of β-peptido sugar-copolymers through anionic ring-opening polymerization (ROP) of β-lactams
Implementation Method 2
creating a double helical structure that selectively targets bacteria while maintaining biocompatibility with mammalian cells
Data Source
AI summary
There is provided a β-peptido sugar-copolymer having the structure of formula (I) as defined herein, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of the same. There is provided a process to make the β-peptido sugar-copolymer as defined herein. There are further provided medical applications of the β-peptido sugar-copolymer as defined herein. In a preferred embodiment, a block-like copolymer poly(amido-D-glucose)-block-poly-β-(L)-homolysine (PDGu-b-PBLK) synthesized via anionic ring-opening polymerization (ROP) demonstrates an antimicrobial efficacy, an enhanced selectivity towards different bacteria, biocompatibility vs. mammalian cells and spontaneous assembly.